| 1. |
- Eksmyr, R, et al.
(author)
-
Low molecular weight proteinuria and slight hyperlipoproteinemia in three mentally retarded brothers.
- 1976
-
In: Acta paediatrica Scandinavica. - 0001-656X. ; 65:4, s. 521-5
-
Journal article (peer-reviewed)abstract
- Mental retardation in combination with proteinuria and a slight hyperlipoproteinemia was found in three brothers. The increased urinary protein excretion was dominated by albumin and the low molecular weight proteins retinol-binding protein (RBP) and beta2-microglobulin, indicating the presence of proximal tubular dysfunction. However, there was no glucosuria, phosphaturia or amino aciduria and the renal concentrating and acidification capacities were normal. A kidney biopsy in one of the patients revealed morphologic evidence of glomerular damage but a normal tubular structure. A mild hyper-beta-lipoproteinemia was found in the patients but not in their healthy siblings. The cause of this syndrome, hitherto not described, is unknown.
|
|
| 2. |
- Johansson, C, et al.
(author)
-
Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract.
- 1978
-
In: Acta medica Scandinavica. - 0001-6101. ; 204:6, s. 509-12
-
Journal article (peer-reviewed)abstract
- An absolute reduction of the plasma cortisol levels and a delay of the peak concentrations were recorded in 10 healthy subjects, when a bile-sequestering anionic exchange resin, cholestyramine, was given prior to a single oral hydrocortisone dose, indicating that the resin interferes with the uptake of a neutral sterol in the human gastrointestinal tract. The possibility of a direct binding of drug to resin is supported by the affinity of hydrocortisone to cholestyramine in vitro, which was uninfluenced by the presence of sodium taurocholate. Cholestyramine significantly delayed the gastric emptying of a glucose solution, indicating that the resin not only decreases but also delays hydrocortisone absorption. Careful supervision is recommended when treatment with cholestyramine is given concomitant to neutral sterol drugs.
|
|
| 3. |
|
|
